Assessing the effectiveness of Upadacitinib for treating atopic dermatitis in adolescents and adults

Non-Interventional, Prospective Observational Cohort Study to Investigate the Effectiveness and Sustained Disease Control of an Upadacitinib Therapy in Moderate to Severe Atopic Dermatitis Patients Over Two Years

Observational AbbVie · NCT05139836

This study tests how well the oral medication Upadacitinib works for treating moderate to severe atopic dermatitis in teenagers and adults who are already using it.

Quick facts

Study typeObservational
Enrollment772 (estimated)
Ages12 Years and up
SexAll
SponsorAbbVie Industry-sponsored
Drugs / interventionsUpadacitinib
Locations125 sites (Heidelberg, Baden-Wuerttemberg and 124 other locations)
Trial IDNCT05139836 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the real-world effectiveness of oral Upadacitinib in treating moderate to severe atopic dermatitis in adolescents and adults. It aims to assess disease activity and response patterns among participants who have been prescribed Upadacitinib prior to enrollment. Approximately 772 participants will be enrolled across up to 200 sites in Germany, providing insights into the medication's utilization in clinical practice.

Who should consider this trial

Good fit: Ideal candidates include adolescents and adults aged 12 years and older with a physician-confirmed diagnosis of moderate to severe atopic dermatitis.

Not a fit: Patients currently participating in interventional research may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable information on the effectiveness of Upadacitinib, leading to improved treatment strategies for patients with atopic dermatitis.

How similar studies have performed: Other studies have shown success with similar approaches in evaluating real-world effectiveness of treatments for atopic dermatitis.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Body weight \>=30 kg at baseline for participants between \>=12 and \<18 years of age.
* Physician confirmed diagnosis of moderate to severe atopic dermatitis at the time of enrollment.
* Upadacitinib initiated as per the local label. The decision to prescribe upadacitinib must have been made prior to and independently of study participation.
* Medical and medication history available at least for the last 6 months.

Exclusion Criteria:

- Current participation in interventional research (note: this does not include non-interventional, post-marketing observational studies, or registry participation).

Where this trial is running

Heidelberg, Baden-Wuerttemberg and 124 other locations

+75 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Atopic DermatitisUpadacitinibRINVOQ
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.